Identification of an ex vivo inhibitor of the schizophrenia biomarker Ndel1 by high throughput screening.

Abstract

Ndel1 oligopeptidase activity shows promise as a potential biomarker for diagnosing schizophrenia (SCZ) and monitoring early-stage pharmacotherapy. Ndel1 plays a pivotal role in critical aspects of brain development, such as neurite outgrowth, neuronal migration, and embryonic brain formation, making it particularly relevant to neurodevelopmental disorders like SCZ. Currently, the most specific inhibitor for Ndel1 is the polyclonal anti-Ndel1 antibody (NOAb), known for its high specificity and efficient anti-catalytic activity. NOAb has been vital in measuring Ndel1 activity in humans and animal models, enabling the prediction of pharmacological responses to antipsychotics in studies with patients and animals. To advance our understanding of in vivo Ndel1 function and develop drugs for mental disorders, identifying small chemical compounds capable of specifically inhibiting Ndel1 oligopeptidase is crucial, including within living cells. Due to challenges in obtaining Ndel1's three-dimensional structure and its promiscuous substrate recognition, we conducted a high-throughput screening (HTS) of 2,400 small molecules. Nine compounds with IC50-values ranging from 7 to 56 μM were identified as potent Ndel1 inhibitors. Notably, one compound showed similar efficacy to NOAb and inhibited Ndel1 within living cells, although its in vivo use may pose toxicity concerns. Despite this, all identified compounds hold promise as candidates for further refinement through rational drug design, aiming to enhance their inhibitory efficacy, specificity, stability, and biodistribution. Our ultimate goal is to develop druggable Ndel1 inhibitors that can improve the treatment and support the diagnosis of psychiatric disorders like SCZ.

• Authors: João V Nani, Camila Coelho, William Y Oyadomari, Thays Calista Santiago, Marcelo Marcondes Machado, Raissa R Christoff, Patrícia P Garcez, Vitor Oliveira, Martin Würtele, Mirian A F Hayashi
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 217 Pg. 115841 (11 2023) ISSN: 1873-2968 [Electronic] England
• PMID: 37820964 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers
• Carrier Proteins
• NDEL1 protein, human
• Antibodies

Topics

• Animals
• Humans
• Biomarkers
• Carrier Proteins (immunology, metabolism)
• High-Throughput Screening Assays
• Schizophrenia (diagnosis, therapy)
• Tissue Distribution
• Antibodies (pharmacology, therapeutic use)